Screening for Anal Cancer and Precancer in Women With HIV (SANCA)

The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches. Secondly the investigators wish to investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV, combining prospective molecular biology analysis with clinical data from registries.

NCT Number	NCT07059442
Lead Sponsor	Karolinska Institutet Collaborators: Karolinska University Hospital, Stockholm South General Hospital, Sahlgrenska University Hospital, The Swedish Research Council
Conditions	Anal Canal Cancer
Enrollment	1,000 participants
Start Date	2025-09-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2035-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-10